{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/prescribing-information/low-dose-aspirin/","result":{"pageContext":{"chapter":{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin","depth":2,"htmlHeader":"<!-- begin field 4772d387-41eb-4ad0-a708-a781008e05c9 --><h2>Low dose aspirin</h2><!-- end field 4772d387-41eb-4ad0-a708-a781008e05c9 -->","summary":"","htmlStringContent":"<!-- begin item a5dac5ef-c72b-4092-aaab-a781008e0464 --><!-- end item a5dac5ef-c72b-4092-aaab-a781008e0464 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"13566b1c-4f29-538c-a3f6-929ea9830db8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7786f354-a7c5-4b24-9e08-a781008f20a4 --><h3>Contraindications and cautions </h3><!-- end field 7786f354-a7c5-4b24-9e08-a781008f20a4 -->","summary":"","htmlStringContent":"<!-- begin item 94934d39-43fb-4dfc-9001-a781008f1fc5 --><!-- begin field c7b8e560-16e5-43cb-a937-a781008f20a4 --><ul><li><strong>Do not prescribe aspirin to children younger than 16 years of age</strong> (unless specifically indicated by a specialist — for example, for Kawasaki's disease).</li><li><strong>Do not prescribe aspirin to people with: </strong><ul><li>A history of true hypersensitivity to aspirin, salicylates or another nonsteroidal anti-inflammatory drug (NSAID).<ul><li>Symptoms of hypersensitivity to aspirin or salicylates include bronchospasm, urticaria, angioedema, and rhinitis. These can occur in isolation or in combination and can lead to severe or life-threatening reactions.</li></ul></li><li>Active pathological bleeding, such as peptic ulcer or intracranial haemorrhage.</li><li>Severe cardiac failure.</li><li>Severe hepatic impairment.</li><li>Severe renal impairment.</li><li>Haemophilia or another haemorrhagic disorder (including thrombocytopenia).</li></ul></li><li><strong>Prescribe aspirin with caution to people with:</strong><ul><li>Anaemia.</li><li>Asthma.</li><li>Dehydration.</li><li>Hepatic impairment.</li><li>Previous peptic ulceration.</li><li>Renal impairment.</li><li>Thyrotoxicosis.</li><li>Uncontrolled hypertension.</li></ul></li><li><strong>Also prescribe aspirin with caution in: </strong><ul><li>The elderly.</li><li>People at high risk of increased bleeding — for example, those receiving treatment with warfarin, nonsteroidal anti-inflammatory drugs, corticosteroids, or other drugs known to increase bleeding.<ul><li>For further information, see <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/prescribing-information/low-dose-aspirin/#drug-interactions\">drug interactions</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field c7b8e560-16e5-43cb-a937-a781008f20a4 --><!-- end item 94934d39-43fb-4dfc-9001-a781008f1fc5 -->","subChapters":[]},{"id":"db057987-dbdf-5991-abc2-41e533a63fd5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a67eb908-d02f-4c06-b1b6-a781008f3b7f --><h3>Adverse effects</h3><!-- end field a67eb908-d02f-4c06-b1b6-a781008f3b7f -->","summary":"","htmlStringContent":"<!-- begin item 9d9770dd-0d55-4992-84c7-a781008f3594 --><!-- begin field 8a1b389e-9638-4bc9-bcba-a781008f3b7f --><ul><li>Adverse effects of low dose aspirin include: <ul><li>Asthma, bronchospasm.</li><li>Gastrointestinal irritation.<ul><li>For further information, see <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/#preventing-dyspepsia\">Preventing dyspepsia</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/#managing-antiplatelet-induced-dyspepsia\">Managing antiplatelet-induced dyspepsia</a>.</li></ul></li><li>Haemorrhage, including gastrointestinal haemorrhage (occasionally major), and subconjunctival haemorrhage.</li><li>Increased bleeding time.</li><li>Skin reactions.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 8a1b389e-9638-4bc9-bcba-a781008f3b7f --><!-- end item 9d9770dd-0d55-4992-84c7-a781008f3594 -->","subChapters":[]},{"id":"55f360c7-0694-5fc3-9005-43d15fd41b9c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1030dca1-18d4-46cd-ac46-a781008f5b99 --><h3>Drug interactions</h3><!-- end field 1030dca1-18d4-46cd-ac46-a781008f5b99 -->","summary":"","htmlStringContent":"<!-- begin item eb48ba49-7a3f-424c-959b-a781008f5a5a --><!-- begin field c3bc1e07-4661-4cfc-afd5-a781008f5b99 --><ul><li>The risk of bleeding is increased when low-dose aspirin is combined with other drugs that can increase the risk of bleeding. If these drugs are used concurrently with low-dose aspirin, consider the need for gastroprotection with a proton pump inhibitor (such as omeprazole) or a histamine antagonist (such as ranitidine). Drugs that can increase the risk of bleeding include:<ul><li>Other antiplatelet drugs (such as clopidogrel, prasugrel, or ticagrelor).</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) (for example, ibuprofen).</li><li>Oral and parenteral anticoagulants (for example, warfarin or heparin) — low dose aspirin and oral anticoagulants are usually co-prescribed on the advice of a specialist. Close monitoring is required.</li><li>Selective serotonin reuptake inhibitors (such as fluoxetine), venlafaxine, or duloxetine — consider alternatives that may be safer, such as trazodone, mianserin, mirtazapine, or reboxetine.</li><li>Other drugs known to increase gastrointestinal bleeding (for example, corticosteroids).</li></ul></li><li><strong>Methotrexate</strong> — the toxicity of methotrexate may be enhanced by aspirin. <ul><li>The risk of toxicity is greater in people receiving high doses of methotrexate (150 mg daily or more — used to treat cancer) and in people with renal impairment.</li><li>Ensure that the individual is monitored regularly for adverse effects and is advised on when to seek medical advice (for example, if they have sore throat, dyspnoea, or cough). For further information on monitoring a person taking methotrexate and on the signs of methotrexate toxicity, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a>.</li></ul></li><li><strong>Probenecid</strong> — the uricosuric effect is antagonised if taken concurrently with aspirin. There is no interaction with low dose enteric coated aspirin. </li><li><strong>NSAIDs</strong> — there may be a loss of aspirin antiplatelet effect if taken concurrently with an NSAID.<ul><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li><li>This interaction is thought not to occur with occasional ibuprofen use.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field c3bc1e07-4661-4cfc-afd5-a781008f5b99 --><!-- end item eb48ba49-7a3f-424c-959b-a781008f5a5a -->","subChapters":[]},{"id":"fbc82569-b699-58de-b0f3-4e2228dcdf6f","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 2e9854f8-f00f-41e3-a65c-a8e9007122f7 --><h3>Pregnancy and breastfeeding</h3><!-- end field 2e9854f8-f00f-41e3-a65c-a8e9007122f7 -->","summary":"","htmlStringContent":"<!-- begin item d46537eb-46fd-44d7-bd15-a8e900711ec1 --><!-- begin field 5270d29a-ec24-498a-a92b-a8e9007122f7 --><h4>Pregnancy</h4><ul><li>Low doses (less than 100 mg/day) appear to be safe, but require specialised monitoring.<ul><li> The manufacturer advises that aspirin should not be given in the first and second trimester unless clearly necessary.</li></ul></li><li>Antiplatelet doses should be used with caution in the third trimester.<ul><li>The manufacturer advises that doses of 100 mg/day and higher are contraindicated during the third trimester of pregnancy.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Long-term use of aspirin should be avoided in women who are breastfeeding.<ul><li>Low quantities of salicylates and their metabolites are excreted in breastmilk. Breastfeeding needs to be discontinued if low dose aspirin is used short-term.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 5270d29a-ec24-498a-a92b-a8e9007122f7 --><!-- end item d46537eb-46fd-44d7-bd15-a8e900711ec1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}